Federal Trade Commission sues largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in patients paying more for the medications.
Feds sue pharmacy gatekeepers over high insulin costs
The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug prices on behalf of insurers, claiming they are illegally maximizing profits by steering patients to high-cost insulin products.
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...
The Federal Trade Commission is suing the titans of the pharmacy benefit manager industry for anticompetitive practices ...
The Federal Trade Commission's administrative complaint follows an interim report from the agency regarding PBM practices.
Patients remain sidelined in this scheme, as their cost-sharing is based on the list price, not the discounted rate. PBMs have become powerful gatekeepers in the prescription drug market ...
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to ...
For years, these cities and states have insisted on a cut—if not all—of the rebates that these pharmacy benefit managers ... make two claims: that insulin prices are unreasonably high and ...
FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback